Short-, Intermediate-, and Long-Term Changes in Basophil Reactivity Induced by Venom Immunotherapy.
10.4168/aair.2016.8.5.412
- Author:
Ana RODRÍGUEZ TRABADO
1
;
Carmen CÁMARA HIJÓN
;
Alfonso RAMOS CANTARIÑO
;
Silvia ROMERO-CHALA
;
José Antonio GARCÍA-TRUJILLO
;
Luis Miguel FERNÁNDEZ PEREIRA
Author Information
1. Ciudad de Coria Hospital, Allergy Department, Cáceres, Spain. ana.rodriguez@ses.juntaextremadura.net
- Publication Type:Original Article
- Keywords:
Activation;
basophil;
venom;
immunotherapy;
CD63
- MeSH:
Basophils*;
Bites and Stings;
Cross-Sectional Studies;
Diagnosis;
Humans;
Hymenoptera;
Immunotherapy*;
Prospective Studies;
Sensitivity and Specificity;
Venoms*
- From:Allergy, Asthma & Immunology Research
2016;8(5):412-420
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The basophil activation test (BAT) has been used to monitor venom immunotherapy (VIT) due to its high specificity. A previous study has reported a good correlation between a significant decrease in basophil activation during 5 years of VIT and clinical protection assessed by sting challenge. The following prospective study was performed to examine changes in basophil reactivity over a complete VIT period of 5 years. METHODS: BAT in a dose-response curve was studied prospectively in 10 hymenoptera venom-allergic patients over 5 years of VIT. BAT was performed at the time of diagnosis, 1 month after finishing the VIT build-up phase, and 3, 6, 12, 24, and 60 months after beginning treatment. The repeated measures ANOVA was applied to evaluate basophil activation changes throughout VIT. A cross-sectional study was also performed in 6 patients who received treatment for more than 3 years, and in another 12 patients who followed immunotherapy for at least 5 years. RESULTS: An early activation decrease was observed during the first 3 months of treatment, compared to pre-treatment values. This activation decrease was not maintained 6 to 18 months after treatment, but was observed again after 2 years of treatment, and maintained until the completion of the 5-year immunotherapy period. In cross-sectional analysis, the 6 patients who received treatment for 3 years, and 9 of the 12 patients who received treatment for 5 years, had negative BAT results. Three patients in this last group had positive BAT results and 2 patients had systemic reactions after field stings. CONCLUSIONS: BAT appears to be an optimal non-invasive test for close monitoring of VIT.
